ArticleSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society2025
Characterization of soil-derived Bacillus subtilis metabolites against breast cancer: In vitro and in silico studies.
Article in Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Preferential localization of intratumoural bacteria in breast cancer revealed by fluorescence in situ hybridization.World journal of microbiology & biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer remains one of the most challenging and widespread cancers among women globally that warrants further investigations for novel agents to minimize side effects and disease recurrence. In this study, a soil bacterium was isolated and 16S rRNA nucleotide sequence homology and resultant phylogenetic tree analysis confirmed Bacillus subtills (CP020102.1). The crude extract of bacterial strain showed cytotoxicity (cell viability 63.1%) against human breast cancer cell line MCF-7 through MTT assay followed by further analysis through preparative HPLC showing 29 active fractions. Among all fractions, fraction 16 demonstrated cytotoxic potential as low as 54.03%. The spectral data of LC-MS, NMR and FTIR identified the bioactive compound as isatin based bacterial metabolite (Z)-N'-(1-hexyl-2-oxoindolin-3-ylidene)-4-methylbenzenesulfonohydrazide. This bioactive compound upon in silico docking analysis with HER2 showed a binding energy of -8.8 kcal/mol. ADMET calculations determined the pharmacokinetic behavior of the compound revealing acceptable distribution and absorption profiles. The drug-likeness of the compound was confirmed based on the Lipinski rule with zero violations. Molecular dynamic simulation (MDS) was also performed for 100 ns and a stable RMSF plot was observed. The results strongly propose that the identified compound has immense potential to be considered a drug candidate to develop further against human breast cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.